ARC-8: Targeting CD73 Inhibition in mPDAC With Quemliclustat and Zimberelimab

Gulam Abbas Manji, MD, PhD, discusses the ARC-8 study, which analyzed the efficacy of the novel CD73 inhibitor quemliclustat when used in combination with gemcitabine/nab-paclitaxel with and without zimberelimab.

He elaborates on the rationale behind targeting CD73 inhibition with standard-of-care chemotherapy and anti-PD-1 therapy, and describes the initial efficacy results of the study.

Dr. Manji serves as the Director of Pancreas Medical Oncology and Director of GI Medical Oncology at Columbia University Irving Medical Center.

View his further comments on gemcitabine with CXCR4 for PDAC.